Amneal Pharmaceuticals
AMRX
127 hedge funds and large institutions have $342M invested in Amneal Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 28 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 28
2% less funds holding
Funds holding: 129 → 127 (-2)
8.68% less ownership
Funds ownership: 75.43% → 66.75% (-8.7%)
30% less capital invested
Capital invested by funds: $488M → $342M (-$145M)
47% less call options, than puts
Call options by funds: $305K | Put options by funds: $574K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.36M |
| 3 |
Neuberger Berman Group
New York
|
+$1.32M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.05M |
| 5 |
PCM
Prelude Capital Management
New York
|
+$918K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.29M |
| 2 |
MSL
Mackay Shields LLC
New York
|
-$3.78M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.94M |
| 4 |
Two Sigma Investments
New York
|
-$2.56M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.64M |
AMRX Hedge Fund Activity: Q1 2020 in Review
127 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2020, worth a combined $342M — down 30% from $488M a quarter earlier.
Fund positioning in AMRX was balanced in Q1 2020: 28 funds opened new positions, 28 closed out, 38 added to existing stakes and 36 trimmed.
The largest buyer was Federated Hermes, adding an estimated $4.44M. The largest seller was Millennium Management, exiting entirely with an estimated $8.29M sold.
- 127 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2020, down from 129 in Q4 2019.
- Funds reported $342M of Amneal Pharmaceuticals stock for Q1 2020, down 30% quarter-over-quarter.
- 28 funds opened new Amneal Pharmaceuticals positions in Q1 2020 and 28 closed out, a net change of 0 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2020 was Federated Hermes, an estimated $4.44M added.
- The largest Amneal Pharmaceuticals seller in Q1 2020 was Millennium Management, an estimated $8.29M sold.
Based on aggregated 13F filings for Q1 2020.